Abstract
Objectives Based on clinical, biomarker and genetic data, autoimmune and autoinflammatory disorders (AIDs) can be classified as a disease continuum from pure autoinflammatory to pure autoimmune with mixed diseases in between. However, the genetic architecture of AIDs has not been systematically described. Here we investigate the polygenic continuum of AIDs using genome-wide association studies (GWAS) and statistical genetics methods.
Methods We mapped the genetic landscape of 15 AIDs using GWAS summary statistics and methods including genomic structural equation modelling (genomic SEM), linkage disequilibrium score regression, Local Analysis of [co]Variant Association, and Gaussian causal mixture modelling (MiXeR). We performed enrichment analyses of tissues and biological gene-sets using MAGMA.
Results Genomic SEM suggested a continuum structure with four underlying latent factors from autoimmune diseases at one end to autoinflammatory on the opposite end. Across AIDs, we observed a balanced mixture of negative and positive local correlations within the major histocompatibility complex, while outside this region they were predominantly positive. MiXeR analysis showed large genetic overlap in accordance with the continuum landscape. MAGMA analysis implicated genes associated with monogenic immune diseases in autoimmune (factor 1) and autoinflammatory diseases (factor 4).
Conclusions Our findings support a polygenic continuum across AIDs, with four genetic clusters. The “polygenic autoimmune” and “polygenic autoinflammatory” clusters reside on margins of this continuum. The identified genetic patterns across different AIDs can potentially guide drug selection, as patients within the same clusters may benefit from the same therapies.
Competing Interest Statement
O.A.A. has received speaker fees from Lundbeck, Janssen, Otsuka, and Sunovion and is a consultant to Cortechs.ai. and Precision Health. Dr. Frei is a consultant to Precision Health. Remaining authors have no conflicts of interest to declare.
Funding Statement
This study was funded by RCN 223273, 248778, 300309, 324252, 324499, 326813, 344121, European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie Actions Grant 801133 (Scientia fellowship), under grant agreement 847776 and 964874, the South-East Norway Regional Health Authority (2022073 and 2023087), KG Jebsen Stiftelsen. This project has received funding from EEA grants (EEA-RO-NO-2018-0535, EEA-RO-NO-2018-0573). This work was partly performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo and operated and developed by the TSD service group at the University of Oslo, IT Department (USIT), with resources provided by UNINETT Sigma2 - the National Infrastructure for High Performance Computing and Data Storage in Norway. Computations were also performed on resources provided by the National Infrastructure for High-Performance Computing and Data Storage in Norway.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GWAS data (summary statistics) are publicly available on GWAS catalog https://www.ebi.ac.uk/gwas/ or FinnGen database https://www.finngen.fi/en, or IMSGC database https://imsgc.net/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The new version has minor changes in figs, grammar, and spelling that were revealed at the stage of journal submission.
Data Availability
GWAS data (summary statistics) are publicly available on GWAS catalog https://www.ebi.ac.uk/gwas/ or FinnGen database https://www.finngen.fi/en, or IMSGC database https://imsgc.net/. All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- AD
- autoimmune diseases
- AIC
- Akaike Information Criterion
- AIDs
- autoimmune and autoinflammatory disorders
- AIF
- autoinflammatory disorders
- AITD
- autoimmune thyroiditis
- EFA
- exploratory and confirmatory factor analysis
- CeD
- celiac disease
- CD
- Crohn’s disease
- CFA
- confirmatory factor analysis
- CFI
- Comparative Fit Index
- CNS
- central nervous system
- Genomic SEM
- genomic structural equation modelling
- IL
- interleukin
- JAK
- Janus kinase
- JIA
- juvenile idiopathic arthritis
- LAVA
- Local Analysis of [co]Variant Association
- LD
- linkage disequilibrium
- LDSC
- linkage disequilibrium score regression
- MHC
- major histocompatibility complex
- MS
- multiple sclerosis
- MiXeR
- Gaussian causal mixture modelling
- MG
- myasthenia gravis
- PBC
- primary biliary cholangitis
- PS
- psoriasis
- PSC
- primary sclerosing cholangitis
- RA
- rheumatoid arthritis
- SjS
- primary Sjogren’s syndrome
- SLE
- systemic lupus erythematosus
- SRMR
- standardised root mean square residual
- SS
- systemic sclerosis
- T1D
- type 1 diabetes
- UC
- ulcerative colitis
